You are here: Home » Reuters » News
Business Standard

Sun Pharma says U.S. FDA clears Halol plant

Reuters  |  MUMBAI 

(Reuters) - India's largest drugmaker Industries Ltd said on Tuesday the U.S. (FDA) cleared its drug plant, which had been under supply restrictions due to quality control failures.

Sun will now be able to restart supplies to its largest market, the United States, from the facility in which contributed around 15 percent to the company's U.S. revenue in 2015.

The FDA issued the company with a warning letter that year following an inspection that revealed manufacturing quality failures at

The company has been working on fixing problems the agency identified. The FDA inspected the plant again in February.

"The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed," Sun said in a statement.

(Reporting by in Mumbai; editing by Jason Neely)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, June 12 2018. 17:45 IST